After slimming down workforce, Aardvark scraps phase 3 trials as wait for next steps drags on

Aardvark Therapeutics has confirmed it is walking away from recently terminated phase 3 trials, telling investors it has no plans to resume the studies “as previously designed” as it works to find a path forward for its stalled pipeline.